CDNA CareDx, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1217234 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.9%
TTM net income YoY111.7%
TTM EPS YoY85.2%
Revenue 3-yr CAGR18.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin23.4%
Net margin25.9%
FCF margin—
EBITDA margin27.0%
Returns
ROE33.0%
ROA24.0%
ROIC (approx.)53.4%
Asset turnover0.93x
Leverage & solvency
Liabilities / assets27.1%
Debt / equity0.00x
Current ratio2.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.54x
Accruals ratio11.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $379.81M | $333.79M | $280.32M | $321.79M | $296.40M |
| R&D expense | $71.43M | $72.51M | $82.42M | $90.39M | $76.53M |
| SG&A expense | $107.56M | $125.14M | $118.84M | $100.40M | $74.96M |
| Operating income | -$30.78M | $40.77M | -$203.36M | -$77.23M | -$29.73M |
| Pretax income | -$21.08M | $52.86M | -$190.14M | -$76.23M | -$32.09M |
| Income tax | $271,000 | $310,000 | $141,000 | $379,000 | -$1.43M |
| Net income | -$21.35M | $52.55M | -$190.28M | -$76.61M | -$30.66M |
| EBITDA | -$15.76M | $54.96M | -$188.98M | -$65.64M | -$20.93M |
| EPS (basic) | -0.40 | 1.00 | -3.54 | -1.44 | -0.59 |
| EPS (diluted) | -0.40 | 0.93 | -3.54 | -1.44 | -0.59 |
| Weighted avg. shares (diluted) | 53.29M | 56.62M | 53.76M | 53.32M | 52.24M |
| Balance sheet | |||||
| Cash & equivalents | $65.43M | $115.27M | $82.20M | $90.44M | $348.70M |
| Short-term investments | $111.78M | $145.96M | $153.22M | $203.17M | $0 |
| Receivables | $42.63M | $64.61M | $51.06M | $66.31M | $59.76M |
| Inventory | $26.70M | $19.50M | $19.47M | $19.23M | $17.19M |
| Current assets | $257.13M | $351.83M | $313.71M | $387.85M | $433.36M |
| PP&E, net | $32.97M | $33.55M | $35.25M | $35.53M | $22.04M |
| Goodwill | $40.34M | $40.34M | $40.34M | $37.52M | $36.98M |
| Intangibles | $31.96M | $38.18M | $45.70M | $43.05M | $50.20M |
| Total assets | $413.23M | $491.05M | $466.83M | $542.99M | $566.62M |
| Current liabilities | $89.85M | $89.37M | $78.07M | $75.97M | $77.30M |
| Total liabilities | $110.13M | $112.62M | $205.50M | $112.08M | $100.75M |
| Shareholders' equity | $303.10M | $378.43M | $261.33M | $430.91M | $465.88M |
| Shares outstanding | 50.92M | 54.77M | 51.50M | 53.53M | 52.92M |
| Cash flow statement | |||||
| Operating cash flow | $42.03M | $38.05M | -$18.39M | -$25.24M | -$19.29M |
| Investing cash flow | $2.16M | -$483,000 | $40.45M | -$228.50M | $47.71M |
| Financing cash flow | -$93.39M | -$5.61M | -$29.61M | -$4.54M | $185.64M |
| Depreciation & amortization | $15.02M | $14.19M | $14.39M | $11.60M | $8.80M |
| Stock-based compensation | $34.86M | $66.41M | $49.09M | $46.55M | $36.08M |
| Share buybacks | $87.77M | $522,000 | $27.54M | $642,000 | $0 |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.